-

Prothena to Participate in 2023 Bank of America Healthcare Conference

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on Tuesday, May 9, 2023 at 9:20 AM PT.

A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts

Investors
IR@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com

Prothena Corporation plc

NASDAQ:PRTA

Release Summary
Prothena today announced that members of its management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference.
Release Versions
$Cashtags
Hashtags

Contacts

Investors
IR@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com

Social Media Profiles
More News From Prothena Corporation plc

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

DUBLIN, Ireland--(BUSINESS WIRE)--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025...

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

DUBLIN--(BUSINESS WIRE)--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation....

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights....
Back to Newsroom